Streptozotocin resistant pancreatic neuroendocrine tumor cell lines as a tool to understand chemotherapy resistance in pNET

#3252

Introduction: Streptozotocin based chemotherapy is standard of care in patients with advanced pancreatic neuroendocrine tumors (pNET). Although partial remission can initially be achieved in up to 40% of patients, primary non-responders and development of secondary progression under therapy is a major clinical challenge. So far, the mechanism leading to streptozotocin resistance have not been elucidated.

Aim(s): The aim of the study was to identify mechanism of streptozotocin resistance development in pNET cells.

Materials and methods: PNET cell lines NT-3, NT-18LM and BON were cultured in the presence of increasing doses of streptozotocin. Ensuing streptozotocin tolerant sub cell lines were evaluated by streptozotocin dose response curves and expression profiling of DNA repair genes.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Schrader J

Authors: Viol F, Amin T, Fahl M, Izbicki J, Schrader J,

Keywords: streptozotocin, pNET, MGMT,